Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

被引：0
|
作者：
Farber, Harrison W. [1 ]
Germack, Hayley D. [2 ]
Croteau, Nicole S. [3 ]
Simeone, Jason C. [3 ]
Tang, Fei [3 ]
Paoli, Carly J. [2 ]
Doad, Gurinderpal [4 ]
Panjabi, Sumeet [2 ]
De Marco, Teresa [5 ]
机构：
[1] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02111 USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] Cytel, Real World Evidence, Waltham, MA USA
[4] Actelion Pharmaceut, Titusville, NJ USA
[5] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA
来源：
PULMONARY CIRCULATION | 2024年 / 14卷 / 02期
关键词：
pulmonary arterial hypertension; risk factors; treatment;
D O I：
10.1002/pul2.12326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension
    Narechania, Shraddha
    Torbic, Heather
    Tonelli, Adriano R.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (02) : 131 - 141
  • [2] Treatment patterns and factors associated with adherence in pulmonary arterial hypertension
    Albanell-Fernandez, Marta
    Mestre, Maria Margalida
    Lopez, Belen
    Gonzalez-Garcia, Ruben
    Planas, Jaume
    Serrano, Marta
    Wilhelmi, Emma
    Lizondo, Thais
    Soy, Dolors
    Martin-Conde, Maite
    FARMACIA HOSPITALARIA, 2025, 49 (02) : 72 - 78
  • [3] Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
    Chaturvedi, Abhishek
    Kanwar, Manreet
    Chandrika, Parul
    Thenappan, Thenappan
    Raina, Amresh
    Benza, Raymond L.
    DATA IN BRIEF, 2020, 32
  • [4] Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases
    Boueiz, Adel
    Hassoun, Paul M.
    ANNALS OF THORACIC MEDICINE, 2014, 9 (05) : 26 - 37
  • [5] Treatment of pulmonary arterial hypertension associated to systemic sclerosis
    Hachulla, E
    REVUE DE MEDECINE INTERNE, 2004, 25 (03): : 195 - 200
  • [6] Pulmonary arterial hypertension: diagnosis and treatment
    Sadowski, Marcin
    Janion-Sadowska, Agnieszka
    Letek, Agnieszka
    Raczynski, Grzegorz
    Zandecki, Lukasz
    MEDICAL STUDIES-STUDIA MEDYCZNE, 2013, 29 (03) : 273 - 279
  • [7] Selexipag for the treatment of pulmonary arterial hypertension
    Richter, Manuel Jonas
    Gall, Henning
    Grimminger, Jan
    Grimminger, Friedrich
    Ghofrani, Hossein-Ardeschir
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (13) : 1825 - 1834
  • [8] Current Treatment of the Pulmonary Arterial Hypertension
    Gallego-Page, Juan C.
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2007, 3 (02) : 129 - 134
  • [9] Bosentan for the treatment of pulmonary arterial hypertension associated to scleroderma
    Hachulla, E.
    Launay, D.
    Humbert, M.
    REVUE DE MEDECINE INTERNE, 2007, 28 : S221 - S226
  • [10] Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension
    Johnson, Sindhu R.
    Swinton, John R.
    Granton, John T.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (08) : 1584 - 1590
12345